BGM Group Ltd. (BGM): R&D Expense
$672.7K
Year ended 2025-09-30
-18.1%
3-year compound annual growth
+65.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $672.7K | -50.6% | 2026-07-21, From 2024-10-01 |
| 2024-09-30 | $1.36M | +139.5% | 2026-07-21, From 2023-10-01 |
| 2023-09-30 | $568.5K | -53.6% | 2026-07-21, From 2022-10-01 |
| 2022-09-30 | $1.22M | n/m | 2025-04-03, From 2021-10-01 |
| 2021-09-30 | $8.0K | -85.2% | 2024-02-15, From 2020-10-01 |
| 2020-09-30 | $54.0K | +22.7% | 2023-04-19, From 2019-10-01 |
| 2019-09-30 | $44.0K | n/a | 2021-03-09, From 2018-10-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
Compare BGM, SBFM, VRCA, BFRI side by side · Screen every company in Pharmaceutical Preparations ↗